查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126377

黑色素瘤診斷市場－策略分析與預測（2026-2035）

Melanoma Diagnostics Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

黑色素瘤診斷市場預計將從 2026 年的 49.2 億美元成長到 2035 年的 112.1 億美元，複合年成長率為 9.6%。

在早期檢測、精準腫瘤學和個人化治療策略的推動下，黑色素瘤診斷市場正經歷模式轉移變革。這一市場演變的特點是，人們日益認知到，準確及時的診斷對於提高生存率至關重要，因為早期黑色素瘤如果能夠及早發現，預後非常好。先進影像技術、分子診斷和人工智慧的融合，使得黑色素瘤的檢測和表徵更加快速、準確且易於取得。由於紫外線照射增加、人口老化以及檢測率的提高，黑色素瘤的發生率持續上升，全球醫療系統正在擴展其診斷能力。對數位皮膚鏡、生物標記檢測和伴隨診斷的大量投資，正在推動黑色素瘤診斷成為皮膚腫瘤學和精準醫療的關鍵組成部分。

市場促進因素

  • 全球黑色素瘤發生率的上升是黑色素瘤診斷市場的主要驅動力。日益加重的疾病負擔導致醫療保健系統對早期檢測技術、先進分子診斷和精準腫瘤解決方案的需求持續成長。醫療機構正在擴展其診斷能力，以支援早期檢測和個人化治療策略。這種需求推動了對各種診斷模式產品的需求，並永續擴大了黑色素瘤診斷的應用。皮膚鏡檢查、數位病理學和人工智慧 (AI) 的日益普及，透過提高診斷準確性以及早期發現和介入黑色素瘤，進一步加速了市場成長。非侵入性影像技術減少了不必要的切片檢查，並改善了病變特徵的描述。醫療機構正在採用人工智慧驅動的皮膚成像技術，以提高診斷信心和工作流程效率。診斷設備製造商正在開發先進的成像和人工智慧解決方案，以滿足不斷成長的需求。生物標記檢測和次世代定序的日益普及，為黑色素瘤患者提供了個人化治療方案和伴隨診斷。精準醫療需要闡明精確的分子特徵，以指導標靶治療和免疫療法的決策。醫療機構正在擴大基因組檢測項目，以支持個人化治療策略。診斷設備製造商正在開發伴隨診斷解決方案，以支持治療藥物的核准和商業化。大眾對皮膚癌篩檢的認知不斷提高，促進了定期皮膚科檢查，並推動了全球先進診斷技術的使用。公共衛生宣傳活動提高了篩檢參與率和早期發現率。醫療系統正在擴大皮膚科服務和診斷技術的覆蓋範圍。

市場限制因素

  • 先進分子診斷和基因組檢測的高成本限制了資源匱乏的醫療系統和發展中地區對這些技術的取得。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。在一些國家，創新黑色素瘤診斷技術的保險報銷有限，限制了精準醫療和伴隨診斷檢測的普及。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。經驗豐富的皮膚病理學家和分子診斷專家的短缺影響了及時診斷和先進黑色素瘤檢測流程的實施。專業人員的短缺降低了診斷能力和擴充性。新分子診斷方法的法規核准要求增加了診斷設備製造商的上市時間和研發成本。

對技術和測試方法的深入了解

  • 技術發展趨勢的特徵是數位成像、分子診斷和人工智慧平台的重要性日益凸顯。由於皮膚鏡檢查在臨床實踐中的廣泛應用以及其在黑色素瘤早期檢測中的有效性，它佔據了最大的技術領域。反射式共聚焦顯微鏡（RCM）提供高解析度、非侵入性成像，提高了對可疑病變的診斷信心。免疫組織化學有助於腫瘤表徵和生物標記評估。聚合酶鍊式反應（PCR）和新一代定序（NGS）能夠檢測具有臨床應用價值的基因突變，從而指導標靶治療的選擇。細分市場分析表明，臨床檢測仍然是黑色素瘤檢測的第一步，而皮膚鏡檢查已成為標準的非侵入性診斷技術。組織病理學仍然是確診的黃金標準。隨著基因組分析和伴隨診斷在精準腫瘤學中變得越來越重要，分子診斷成為成長最快的領域。 BRAF突變檢測在生物標記領域佔據主導地位，因為它在識別適合標靶治療的患者方面發揮著至關重要的作用。 NRAS基因突變分析為預後和治療提供了重要資訊。隨著免疫療法的廣泛應用，PD-L1表現檢測的重要性日益凸顯。篩檢是一項關鍵應用，因為早期發現對於改善預後至關重要。醫院和診斷檢查室是主要的終端使用者群體，皮膚科診所和腫瘤中心也不斷拓展其診斷能力。人工智慧的整合應用正變得越來越重要，因為人工智慧驅動的皮膚成像技術能夠提高篩檢的準確性和工作流程的效率。

競爭格局與策略展望

  • 競爭格局涵蓋了成熟的診斷和生命科學公司，以及專注於皮膚病學、分子診斷和數位成像領域的供應商。羅氏開發分子診斷、伴隨診斷、組織學診斷和精準腫瘤學解決方案，以支持黑色素瘤的診斷和標靶治療選擇。賽默飛世爾科技提供分子診斷、定序平台、PCR技術和基因組解決方案，以支持黑色素瘤的生物標記檢測。丹納赫提供基因組技術、分子診斷、病理解決方案和精準醫療平台，以支持腫瘤診斷。安捷倫開發免疫組織化學檢測、病理儀器、基因組技術和伴隨診斷，以支持黑色素瘤的診斷。徠卡生物系統提供癌症診斷的組織病理學儀器、組織染色系統、數位病理平台和工作流程自動化解決方案。 Illumina是NGS技術的領導供應商，能夠為黑色素瘤患者提供全面的基因組分析。每家公司都在透過在人工智慧輔助成像、液態生物檢體和伴隨診斷平台方面的創新來拓展產品系列。在伴隨診斷技術發展和精準腫瘤解決方案需求日益成長的推動下，診斷設備製造商、製藥公司和研究機構之間的策略合作日益增加。近期的一些重要進展包括：Guardant Health 擴展了液態生物檢體功能，以支持固態腫瘤的全面基因組分析；羅氏加強了其伴隨診斷產品組合，以支持精準腫瘤應用；Illumina 擴展了 NGS 應用，用於全面的癌症基因組分析；以及 Thermo Fisher Scientific 為臨床檢查室推出了先進的腫瘤定序流程。

簡明結論

  • 受疾病發病率上升、技術創新和精準醫療整合的推動，黑色素瘤診斷市場預計將持續成長。從傳統診斷方法轉向非侵入性、基於分子技術的整合策略，標誌著皮膚腫瘤學領域的根本性變革。儘管高成本、有限的保險報銷和人才短缺等挑戰依然存在，但對技術、夥伴關係和臨床檢驗的策略性投資正在為市場領先企業創造永續的競爭優勢。長期市場前景仍然樂觀，黑色素瘤診斷正發展成為精準腫瘤學的關鍵組成部分，為全球醫療保健系統的早期檢測、治療方案選擇和患者預後改善提供支持。

本報告的主要益處：

  • 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
  • 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策，以開發新的收入來源。
  • 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

    產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

  • 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
  • 競爭對手定位、策略和市場佔有率分析
  • 營收成長率及預測分析：依業務板塊及地區（國家）分類
  • 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

  • 市場概述
  • 主要分析結果
  • 分析師意見
  • 策略建議

第2章 分析方法

  • 分析設計
  • 資料收集和分析方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章 全球黑色素瘤診斷市場：概況、市場規模與預測

  • 市場定義和範圍
  • 行業概覽
  • 疾病演變與診斷趨勢
  • 主要市場趨勢
  • 實際成果值市場規模分析
  • 市場預測
  • 疾病盛行率分析
  • 已確診患者族群的分析
  • 對所進行的黑色素瘤診斷測試數量的分析
  • 患者診斷路徑分析

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 新興技術
  • 產品創新
  • 人工智慧驅動的皮膚病變分析
  • 數位皮膚鏡技術
  • 分子診斷檢測
  • 液態生物檢體和生物標記開發
  • 技術藍圖

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：全球黑色素瘤診斷市場：展望分析

  • 分析：按診斷方式
    • 臨床試驗
    • 皮膚鏡檢查
    • 組織病理學
    • 分子診斷
    • 診斷影像
  • 分析：按技術
    • 皮膚鏡檢查
    • 反射式共聚焦顯微鏡（RCM）
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
  • 分析：透過生物標記
    • BRAF突變
    • NRAS突變
    • KIT基因突變
    • PD-L1表達
    • 其他生物標記
  • 分析：透過臨床應用
    • 篩檢
    • 初步診斷
    • 預後評估
    • 治療方案
    • 疾病監測

第9章 全球黑色素瘤診斷市場：細分市場分析

  • 依產品
    • 裝置
    • 試劑和耗材
    • 軟體
  • 透過技術
    • 皮膚鏡檢查
    • 反射式共聚焦顯微鏡（RCM）
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 其他技術
  • 最終用戶
    • 醫院
    • 診斷檢查室
    • 皮膚科診所
    • 癌症中心
    • 學術研究機構

第10章：全球黑色素瘤診斷市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章：全球黑色素瘤診斷市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 澳洲
  • 日本
  • 中國
  • 韓國
  • 印度
  • 巴西
  • 墨西哥
  • 沙烏地阿拉伯
  • 南非

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 企業合併、商業夥伴關係和合作
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Leica Biosystems
  • Illumina, Inc.
  • QIAGEN NV
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Veracyte, Inc.
  • 3Gen, Inc.
  • Canfield Scientific, Inc.
  • bioMerieux
  • Fujifilm Holdings Corporation

第14章：全球黑色素瘤診斷市場：商業預測分析

第15章：投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009089

The Melanoma Diagnostics Market is set to reach USD 11.21 billion in 2035, growing at a CAGR of 9.6 % from USD 4.92 billion in 2026.

The melanoma diagnostics market is undergoing significant transformation driven by the paradigm shift toward early detection, precision oncology, and personalized treatment strategies. The market's evolution is characterized by the growing recognition that accurate and timely diagnosis is essential for improving survival outcomes, as early-stage melanoma has excellent prognosis when identified promptly. The convergence of advanced imaging technologies, molecular diagnostics, and artificial intelligence is enabling faster, more accurate, and increasingly accessible melanoma detection and characterization. Healthcare systems worldwide are expanding diagnostic capabilities as melanoma incidence continues to rise due to increased ultraviolet radiation exposure, aging populations, and improved detection rates. The market is witnessing significant investment in digital dermoscopy, biomarker testing, and companion diagnostics, positioning melanoma diagnostics as a critical component of dermatological oncology and precision medicine.

Market Drivers

  • The increasing global melanoma incidence represents the primary driver for the melanoma diagnostics market. Rising disease burden creates sustained demand for early detection technologies, advanced molecular diagnostics, and precision oncology solutions across healthcare systems. Healthcare providers are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in melanoma diagnostic utilization. The growing adoption of dermoscopy, digital pathology, and artificial intelligence is further accelerating market growth through improved diagnostic accuracy and earlier melanoma identification and intervention. Non-invasive imaging technologies reduce unnecessary biopsies and improve lesion characterization. Healthcare providers are adopting AI-assisted skin imaging to enhance diagnostic confidence and workflow efficiency. Diagnostic manufacturers are developing advanced imaging and AI solutions to capture growing demand. The expanding use of biomarker testing and next-generation sequencing is enabling personalized treatment selection and companion diagnostic adoption for melanoma patients. Precision medicine requires accurate molecular characterization to guide targeted therapy and immunotherapy decisions. Healthcare providers are expanding genomic testing programs to support personalized treatment strategies. Diagnostic manufacturers are developing companion diagnostic solutions to support therapeutic approvals and commercialization. Rising public awareness regarding skin cancer screening encourages routine dermatological examinations and increases utilization of advanced diagnostic technologies worldwide. Public health campaigns are increasing screening participation and early detection. Healthcare systems are expanding access to dermatological services and diagnostic technologies.

Market Restraints

  • High costs associated with advanced molecular diagnostics and genomic testing limit accessibility across resource-constrained healthcare systems and developing regions. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited reimbursement for innovative melanoma diagnostic technologies restricts adoption of precision medicine and companion diagnostic testing in several countries. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Shortage of experienced dermatopathologists and molecular diagnostic specialists affects timely diagnosis and implementation of advanced melanoma testing workflows. The limited availability of specialized personnel reduces diagnostic capacity and scalability. Regulatory approval requirements for novel molecular diagnostics increase commercialization timelines and development costs for diagnostic manufacturers.

Technology and Modality Insights

  • The technology landscape is characterized by the growing importance of digital imaging, molecular diagnostics, and AI-enabled platforms. Dermoscopy accounts for the largest technology segment owing to its widespread clinical adoption and effectiveness in early melanoma detection. RCM provides high-resolution, non-invasive imaging that improves diagnostic confidence for suspicious lesions. Immunohistochemistry supports tumor characterization and biomarker assessment. PCR and NGS enable detection of clinically actionable genetic mutations that guide targeted therapy selection. The segment analysis reveals that clinical examination remains the initial step in melanoma detection, while dermoscopy has become the standard non-invasive diagnostic technique. Histopathology continues to serve as the gold standard for definitive diagnosis. Molecular diagnostics represent the fastest-growing segment as genomic profiling and companion diagnostics gain importance in precision oncology. BRAF mutation testing dominates the biomarker segment because of its critical role in identifying patients eligible for targeted therapies. NRAS mutation analysis provides important prognostic and therapeutic insights. PD-L1 expression testing continues to gain significance as immunotherapy adoption expands. Screening represents a critical application because of the importance of early detection in improving outcomes. Hospitals and diagnostic laboratories represent the leading end-user segments, with dermatology clinics and cancer centers expanding diagnostic capabilities. The integration of AI is becoming increasingly important as AI-assisted skin imaging improves screening accuracy and workflow efficiency.

Competitive and Strategic Outlook

  • The competitive landscape features established diagnostics and life science companies alongside specialized dermatology, molecular, and digital imaging providers. Roche develops molecular diagnostics, companion diagnostics, tissue diagnostics, and precision oncology solutions supporting melanoma diagnosis and targeted treatment selection. Thermo Fisher Scientific provides molecular diagnostics, sequencing platforms, PCR technologies, and genomic solutions supporting melanoma biomarker testing. Danaher offers genomics technologies, molecular diagnostics, pathology solutions, and precision medicine platforms supporting oncology diagnostics. Agilent develops immunohistochemistry assays, pathology instruments, genomic technologies, and companion diagnostics supporting melanoma diagnosis. Leica Biosystems provides histopathology instruments, tissue staining systems, digital pathology platforms, and workflow automation for cancer diagnostics. Illumina is a leading provider of NGS technologies enabling comprehensive genomic profiling for melanoma patients. Companies are pursuing product portfolio expansion through innovation in AI-assisted imaging, liquid biopsy, and companion diagnostic platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding liquid biopsy capabilities supporting comprehensive solid tumor genomic profiling. Roche enhanced its companion diagnostics portfolio supporting precision oncology applications. Illumina expanded NGS applications for comprehensive cancer genomic profiling. Thermo Fisher Scientific introduced advanced oncology sequencing workflows for clinical laboratories.

Short Conclusion

  • The melanoma diagnostics market is positioned for sustained growth driven by the convergence of rising disease incidence, technological innovation, and precision medicine. The transition from conventional diagnostic approaches toward integrated non-invasive and molecular strategies represents a fundamental shift in dermatological oncology. While challenges related to high costs, reimbursement limitations, and workforce shortages persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with melanoma diagnostics evolving into a critical component of precision oncology, supporting early detection, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Global Melanoma Diagnostics Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Disease Overview
  • 3.3 Disease Evolution and Diagnostic Landscape
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast (2026-2035)
  • 3.7 Disease Prevalence Analysis
  • 3.8 Diagnosed Patient Population Analysis
  • 3.9 Melanoma Diagnostic Testing Volume Analysis
  • 3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies
  • 6.2 Product Innovation
  • 6.3 AI-Assisted Skin Lesion Analysis
  • 6.4 Digital Dermoscopy Technologies
  • 6.5 Molecular Diagnostic Assays
  • 6.6 Liquid Biopsy and Biomarker Development
  • 6.7 Technology Roadmap

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Global Melanoma Diagnostics Market Landscape Analysis

  • 8.1 Analysis by Diagnostic Modality
    • 8.1.1 Clinical Examination
    • 8.1.2 Dermoscopy
    • 8.1.3 Histopathology
    • 8.1.4 Molecular Diagnostics
    • 8.1.5 Imaging Diagnostics
  • 8.2 Analysis by Technology
    • 8.2.1 Dermoscopy
    • 8.2.2 Reflectance Confocal Microscopy (RCM)
    • 8.2.3 Immunohistochemistry (IHC)
    • 8.2.4 Polymerase Chain Reaction (PCR)
    • 8.2.5 Next-Generation Sequencing (NGS)
  • 8.3 Analysis by Biomarker
    • 8.3.1 BRAF Mutation
    • 8.3.2 NRAS Mutation
    • 8.3.3 KIT Mutation
    • 8.3.4 PD-L1 Expression
    • 8.3.5 Other Biomarkers
  • 8.4 Analysis by Clinical Application
    • 8.4.1 Screening
    • 8.4.2 Primary Diagnosis
    • 8.4.3 Prognostic Assessment
    • 8.4.4 Treatment Selection
    • 8.4.5 Disease Monitoring

9. Global Melanoma Diagnostics Market Segment Analysis (2021-2035)

  • 9.1 By Product
    • 9.1.1 Instruments
    • 9.1.2 Reagents & Consumables
    • 9.1.3 Software
  • 9.2 By Technology
    • 9.2.1 Dermoscopy
    • 9.2.2 Reflectance Confocal Microscopy (RCM)
    • 9.2.3 Immunohistochemistry (IHC)
    • 9.2.4 Polymerase Chain Reaction (PCR)
    • 9.2.5 Next-Generation Sequencing (NGS)
    • 9.2.6 Other Technologies
  • 9.3 By End User
    • 9.3.1 Hospitals
    • 9.3.2 Diagnostic Laboratories
    • 9.3.3 Dermatology Clinics
    • 9.3.4 Cancer Centers
    • 9.3.5 Academic & Research Institutes

10. Global Melanoma Diagnostics Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Global Melanoma Diagnostics Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Australia
  • 11.9 Japan
  • 11.10 China
  • 11.11 South Korea
  • 11.12 India
  • 11.13 Brazil
  • 11.14 Mexico
  • 11.15 Saudi Arabia
  • 11.16 South Africa

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd.
    • 13.1.1 Company Overview
    • 13.1.2 Financials
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Developments
  • 13.2 Thermo Fisher Scientific Inc.
    • 13.2.1 Company Overview
    • 13.2.2 Financials
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Developments
  • 13.3 Danaher Corporation
    • 13.3.1 Company Overview
    • 13.3.2 Financials
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Developments
  • 13.4 Agilent Technologies, Inc.
    • 13.4.1 Company Overview
    • 13.4.2 Financials
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Developments
  • 13.5 Leica Biosystems
    • 13.5.1 Company Overview
    • 13.5.2 Financials
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Developments
  • 13.6 Illumina, Inc.
    • 13.6.1 Company Overview
    • 13.6.2 Financials
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Developments
  • 13.7 QIAGEN N.V.
    • 13.7.1 Company Overview
    • 13.7.2 Financials
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Developments
  • 13.8 Abbott Laboratories
    • 13.8.1 Company Overview
    • 13.8.2 Financials
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Developments
  • 13.9 Siemens Healthineers AG
    • 13.9.1 Company Overview
    • 13.9.2 Financials
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Developments
  • 13.10 Bio-Rad Laboratories, Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Financials
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Developments
  • 13.11 Veracyte, Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Financials
    • 13.11.3 Product Portfolio
    • 13.11.4 Recent Developments
  • 13.12 3Gen, Inc.
    • 13.12.1 Company Overview
    • 13.12.2 Financials
    • 13.12.3 Product Portfolio
    • 13.12.4 Recent Developments
  • 13.13 Canfield Scientific, Inc.
    • 13.13.1 Company Overview
    • 13.13.2 Financials
    • 13.13.3 Product Portfolio
    • 13.13.4 Recent Developments
  • 13.14 bioMerieux
    • 13.14.1 Company Overview
    • 13.14.2 Financials
    • 13.14.3 Product Portfolio
    • 13.14.4 Recent Developments
  • 13.15 Fujifilm Holdings Corporation
    • 13.15.1 Company Overview
    • 13.15.2 Financials
    • 13.15.3 Product Portfolio
    • 13.15.4 Recent Developments

14. Global Melanoma Diagnostics Market Commercial Forecast Analysis

  • 14.1 Dermoscopy Systems
  • 14.2 Digital Dermoscopy Solutions
  • 14.3 Histopathology-Based Diagnostics
  • 14.4 Molecular Diagnostic Assays
  • 14.5 Next-Generation Sequencing (NGS)-Based Tests
  • 14.6 AI-Based Skin Lesion Assessment Solutions
  • 14.7 Liquid Biopsy and Biomarker Tests

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends